An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 9050-9050 ◽  
Author(s):  
Myung-Ju Ahn ◽  
Jang Ho Cho ◽  
Jong-Mu Sun ◽  
Se-Hoon Lee ◽  
Jin Seok Ahn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Lung Cancer Patients ◽  
Multicenter Phase

Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation

Chemotherapy ◽  
2013 ◽  
Vol 59 (6) ◽  
pp. 414-419 ◽  
Author(s):  
Young Hak Kim ◽  
Takashi Nishimura ◽  
Hiroaki Ozasa ◽  
Hiroki Nagai ◽  
Yuichi Sakamori ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Phase Ii Study ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide

Lung Cancer ◽  
2014 ◽  
Vol 86 (1) ◽  
pp. 59-66 ◽  
Author(s):  
Athanasios Kotsakis ◽  
Elisavet Papadimitraki ◽  
Eleni Kyriaki Vetsika ◽  
Despoina Aggouraki ◽  
Eleftheria Kleio Dermitzaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Small Cell ◽  
Immunologic Response ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Cryptic Peptide
Sign in / Sign up

Export Citation Format

Share Document